|Daily Range||$36.74 - $37.01|
|52-Week Range||$32.08 - $38.54|
|Dividend (Yield)||$0.00 (2.2%)|
|Average Daily Volume||833,510|
|Current FY EPS||$1.87|
News & Commentary
Shares of the struggling biopharma ImmunoGen skyrocketed today following a clinical update at the American Society of Clinical Oncology meeting. Here's what you need to know moving forward.
Biotech has produced numerous stocks recently that have doubled or tripled in short periods of time. Here is a look at three small-cap companies with the potential to continue this trend.
The pharmaceutical market is headed for $1.3 trillion by 2016. Here's how globalization is radically changing the game for Big Pharma and Big Biotech players.
Regeneron topped estimates Thursday as Eylea sales continue to soar. But the stock failed to hold its gains, as all eyes appear to now be on the biotech's pipeline.
What are Fidelity's top funds nowadays? Here are nine choices delivering strong performance.
After reporting first-quarter financials Friday, ImmunoGen Inc.'s shares fell despite bullish analyst reports.
Here's what you should know about Exelixis Inc., Corcept Therapeutics, and Array BioPharma's big moves this year.
Immuno-oncology has become a major focus among big pharma companies these days. Should investors jump on this trend?
Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.
Healthcare stocks with plenty of potential -- and low share prices